Globus Medical (GMED) Annual Income Statement (USD)
GMED Quarterly Financials (USD)
Frequently Asked Questions About Globus Medical (GMED) Stock
Globus Medical's (GMED) last reported annual revenue was USD 1.57 Billion.
Globus Medical's (GMED) annual revenue growth rate based on the revenue reported in the past 5 years is : 17.08%
Globus Medical's(GMED) is profitable as of its last reported annual financials.
The net profit margin for Globus Medical's(GMED) from its laster reported year is 7.83%
The return on equity (ROE) for Globus Medical's(GMED) from its last reported annual financials is : 4.21%
The return on assets (ROA) for Globus Medical's(GMED) from its last reported annual financials is : 4.77%
The return on invested capital (ROIC) for Globus Medical's(GMED) from its last reported annual financials is : 2.89%
The Debt to Equity ratio for Globus Medical's(GMED) from its last reported annual financials is : 10.44%
The dividend yield for Globus Medical's(GMED) from its laster reported year is 0.00%
Globus Medical's(GMED) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for GMED !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
